Abstract: The present disclosure describes systems, apparatuses, and methods for obfuscation-based intellectual property (IP) watermark labeling. One such method comprises identifying, by one or more computing processors, a specific net within an integrated circuit design that is likely to be used in a malicious attack; and adding additional nets to the integrated circuit design that add additional logic states to a finite state machine present in the integrated circuit design. The additional logic states comprise watermarking states for performing authentication of the integrated circuit design, in which a watermark digest can be captured upon application of secret key inputs to the additional nets. Other methods, systems, and apparatuses are also presented.

Abstract: The disclosure relates to macrocyclic peptides and pharmaceutical compositions thereof. The disclosure further relates to pharmaceutical compositions for modulating opioid receptor activity. The macrocyclic tetrapeptides provided herein are useful in treating diseases or disorders relating to the activity of one or more opioid receptors, such as neurological disorders.

Abstract: Provided herein are modified recombinant adeno-associated virus (rAAV) capsid proteins, such as modified rAAV1, rAAV5, and rAAV6 capsid proteins, rAAV particles comprising such capsid proteins, nucleic acid molecules encoding such capsid proteins, as well as compositions, kits and methods of use thereof.

Abstract: Provided herein are polynucleic acids and expression vectors for the expression and secretion of angiotensin peptide fragments (e.g., angiotensin-(1-7)) in probiotic bacteria. Provided herein are also probiotic compositions that enable efficient, cost-effective and patient friendly oral therapeutics for treating diverse pathological conditions that involve the renin-angiotensin system (RAS), e.g., pulmonary hypertension, diabetes, diabetic complications, cardiovascular diseases, and ocular inflammatory and neurodegenerative diseases.

Abstract: The present disclosure describes various embodiments of systems, apparatuses, and methods for implementing an array antenna having a combination of ferromagnetic and nonferromagnetic conductors in alternating multilayers. One such antenna device comprises an array of patch antennas on a substrate, wherein the patch antennas are formed of a combination of ferromagnetic and nonferromagnetic conductors in alternating multilayers; and a microstrip feeding line coupled to the array of patch antennas. Other systems, apparatuses, and methods are also presented.

Abstract: Various examples are provided for accurate heart rate measurement. In one example, a method includes determining a respiratory rate (RR) and respiration displacement from radar-measured cardiorespiratory motion data; adjusting notch depths of a harmonics comb notch digital filter (HCNDF) based upon the respiration displacement; generating filtered cardiorespiratory data by filtering the radar-measured cardiorespiratory motion data with the HCNDF; and identifying a heart rate (HR) from the filtered cardiorespiratory data. In another example, a system includes radar circuitry configured to receive a cardiorespiratory motion signal reflected from a monitored subject; and signal processing circuitry configured to determine a respiration displacement based upon the cardiorespiratory motion signal; adjust notch depths of a HCNDF based upon the respiration displacement; filter the cardiorespiratory motion data with the HCNDF; and identifying a heart rate (HR) from the filtered cardiorespiratory data.

Abstract: Disclosed are methods and compositions for preventing, treating, and/or ameliorating one or more symptoms of inflammation in a mammal. In particular, viral vectors and medicaments containing them are disclosed, which are useful in the prophylaxis, therapy, or amelioration of symptoms of one or more inflammatory-mediated mammalian diseases, such as age-related macular degeneration (AMD), arthritis, Bechet's disease, Best macular dystrophy, corneal inflammation, diabetic retinopathy, drusen formation, dry AMD, dry eye, geographic atrophy, glaucomaocular neovascularization, Lupus erythematosus, macular degeneration, Mallatia Leventinese and Doyne honeycomb retinal dystrophy, nephritis, ocular hypertension, ocular inflammation, recurrent uveitis, Sorsby fundus dystrophy, vasculitis, vitreoretinopathy, wet AMD, or related disorders.

Abstract: Disclosed are various embodiments of memristive devices comprising a number of nodes. Memristive fibers are used to form conductive and memristive paths in the devices. Each memristive fiber may couple one or more nodes to one or more other nodes. In one case, a memristive device includes a first node, a second node, and a memristive fiber. The memristive fiber includes a conductive core and a memristive shell surrounding at least a portion of the conductive core along at least a portion of the memristive fiber. The memristive fiber couples the first node to the second node through a portion of the memristive shell and at least a portion of the conductive core.

Abstract: Provided herein are modified insecticidal proteins comprising an insecticidal protein, wherein the insecticidal protein has been modified to include at least one stink bug gut binding peptide.

Abstract: Macular degeneration, closed head injury, stroke, irritable bowel disease, and reperfusion injury are all associated with biological injury due to reactive oxygen species, probably due to focal iron overload in many instances. The present invention provides methods and pharmaceutical compositions for treating these diseases and conditions using desferrithiocin analogs of Formula (I). In certain embodiments, the analogs include a poly ether moiety at the 4?-position of the phenyl ring of the compound.

Abstract: Provided herein are genetically engineered cells containing one or more modulated metabolic genes, where the expression of the modulated metabolic gene(s) can be greater than that of an unmodified control. Also provided herein are methods of making the genetically engineered cells using synergistic activation mediator CRISPR-Cas9. Further provided herein are high throughput assays that can employ the genetically engineered cells provided herein.

Abstract: h A method for using a trained machine learning model to predict risk of incident opioid use disorder (OUD) and/or of N an opioid overdose episode for a subject. The method comprises using at least one computer hardware processor to perform: accessing data associated with the subject, wherein the data comprises values for a plurality of predictors; generating input features for the trained machine learning model from the data; and providing the input features as input to the trained machine learning model to obtain an output indicative of the risk of OUD and/or of the opioid overdose episode for the subject, wherein the trained machine learning model comprises a first plurality of values for a respective first plurality of parameters, the first plurality of values used by the at least one computer hardware processor to obtain the output from the input features.

Abstract: The disclosure relates to compounds of Formula (I), as well as compositions, methods, uses, and kits comprising the same. The compounds, compositions, methods, uses, and kits provided herein are useful in treating diseases or disorders including cancer, HIV, and angiogenesis-related disorders.

Abstract: The invention is directed towards compounds, methods of stimulating myelination, stimulating proliferation of oligodendrocytes (OLs) or stimulating oligodendrocyte precursor cells and methods of treating diseases, disorders or symptoms thereof.

Abstract: Biorenewable polyesters and polyester copolymers derived from camphoric acid, aromatic dicarboxylic acid and aliphatic diols and methods of making those copolyesters and articles comprising copolyesters are disclosed. The disclosed biorenewable copolyesters may can have a Mn of from about 5,000 Da to about 500,000 Da. Also disclosed are preparation methods of various monomers e.g., cis-1,4-anhydroerythritol and bis(2-hydroxyethyl) camphorate. The disclosed biorenewable polyesters and polyester copolymers can be used for production of various articles utilizing a conventional polyesters or polyester copolymers, to replace, in part or in whole, a conventional non-biorenewable polyesters or polyester copolymers.

Abstract: Described herein are loupes shields. The shields can be easily attached to the loupes. The loupes shield is composed of a single filter that blocks harmful light. Additionally, the loupes shield includes a connector that permits the loupes shield to be attached to the loupes lens or housing that holds the loupes lens. The loupes shields described are useful in applications where it is desirable to protect the user from being exposed to damaging light. The loupes shields are useful in dental applications such as, for example, dental restorations, where light cure is required to cure the resin applied to a tooth during a dental restoration.

Abstract: Disclosed herein are compounds that selectively bind an expanded transcribed repeat r(G4C2)exp, prevent sequestration of RNA-binding proteins, and inhibit translation of repeat associated non-ATG (RAN) translation responsible for generation of toxic dipeptide repeats underlying diseases such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The compounds and their pharmaceutical compositions are useful in treating a disease or condition characterized by an expanded G4C2 repeat RNA (r(G4C2)exp), such as ALS and FTD.

Abstract: Aspects of the disclosure relate to methods and compositions (e.g., kits) for detecting certain repeat-associated non-ATG (RAN) proteins in a subject (e.g., a subject having or suspected of having a disease associated with a CAG and/or CTG repeat expansion). In some embodiments, methods described by the disclosure comprise detecting one or more RAN proteins in a biological sample obtained from a subject by an immunoassay using one or more antibodies that target homopolymeric repeat regions of RAN proteins. In some embodiments, the disclosure relates to kits comprising one or more antibodies that target homopolymeric repeat regions of RAN proteins, and an immunoassay plate and/or reagents. In some embodiments, the disclosure provides methods of producing anti-RAN protein antibodies.

Abstract: In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, embodiments of the present disclosure, in one aspect, relate to TMJ implantation materials and implants (e.g., temporomandibular joint (TMJ) disc), methods of making TMJ implantation materials and implants, methods of forming a TMJ implantation material or an implant, and the like.

Abstract: An aptamer-N-heterocyclic-carbene metal complex conjugate (aptamer-NHCM conjugate) or an aptamer-bis-N-heterocyclic-carbene metal complex conjugate (aptamer-bis-NHCM conjugate) includes an aptamer coupled through a hydrolytically stable bond to an N-heterocyclic-carbene metal complex (NHCM) or a bis-N-heterocyclic-carbene metal complex (bis-NHCM). The aptamer-NHCM conjugate is prepared where the chosen aptamer displays selective binding to a cell specific receptor, such that the cytotoxic NHCM can be directed specifically to cells responsible for a target disease (e.g., a specific cancer type). A method of preparing the aptamer-N-heterocyclic-carbene metal complex conjugate involves installing a coupling group to an N-heterocyclic-carbene metal complex that can specifically bond with a functional group on an aptamer; the bond, covalent or non-covalent, is stable hydrolytically in the absence of an environment that promotes intentional cleavage of the bond.